Abbott Laboratories $ABT Shares Purchased by Alpine Woods Capital Investors LLC

Alpine Woods Capital Investors LLC boosted its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 1,199.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 43,202 shares of the healthcare product maker's stock after purchasing an additional 39,877 shares during the quarter. Alpine Woods Capital Investors LLC's holdings in Abbott Laboratories were worth $3,920,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. J. Stern & Co. LLP raised its stake in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after buying an additional 39,005,451 shares in the last quarter. Norges Bank acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at $2,938,892,000. BlackRock Inc. grew its position in shares of Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Abbott Laboratories by 217.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker's stock worth $566,967,000 after acquiring an additional 3,780,402 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in Abbott Laboratories by 303.0% in the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker's stock valued at $454,784,000 after acquiring an additional 3,330,368 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott's next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Abbott Laboratories Price Performance

ABT opened at $112.63 on Friday. The stock has a market capitalization of $194.89 billion, a PE ratio of 36.45, a P/E/G ratio of 2.16 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company's 50 day simple moving average is $102.61 and its 200 day simple moving average is $100.22. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company's revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, sell-side analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories's dividend payout ratio is presently 81.55%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ABT shares. Citigroup increased their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a report on Friday, July 17th. Weiss Ratings upgraded shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, August 6th. Wolfe Research upgraded shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price for the company in a research note on Thursday, August 13th. Royal Bank Of Canada reiterated an "outperform" rating and set a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Piper Sandler reissued an "overweight" rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source